 | |
| Clinical data | |
|---|---|
| Other names | Fulvestrant-3-boronic acid; Fulvestrant-3-boronoate; 7α-[9-[(4,4,5,5,5-Pentafluoropentyl)-sulfinyl]nonyl]-3-(dihydroxy-boryl)estra-1,3,5(10)-trien-17β-ol |
| Routes of administration | By mouth[1] |
| Drug class | Antiestrogen;Selective estrogen receptor degrader |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| UNII | |
| Chemical and physical data | |
| Formula | C32H48BF5O4S |
| Molar mass | 634.59 g·mol−1 |
| 3D model (JSmol) | |
| Melting point | 230 °C (446 °F) (decomposes) |
| |
| |
ZB716, also known asfulvestrant-3-boronic acid, is asynthetic,steroidal,orally activeantiestrogen which is under development for the treatment ofestrogen receptor (ER)-positivemetastatic breast cancer.[1] The drug is asilent antagonist of theERα (IC50 = 4.1 nM) as well as aselective estrogen receptor degrader (SERD).[1] It is ananalogue andprodrug offulvestrant in which the C3hydroxyl group has been replaced with aboronic acidmoiety.[1] In accordance, the two drugs have similarpharmacodynamic properties.[1] However, whereas fulvestrant is not orally active and must be administered viaintramuscular injection, ZB716 is less susceptible tofirst-pass metabolism, and in relation to this, is orally active.[1]
A single oral dose of 8.3 mg/kg ZB716 to mice has been found to result in an over 160 ng/mL (160,000 pg/mL)maximal concentration of the drug in circulation, a level far in excess of the 15.2 ng/mL (15,200 pg/mL) concentration achieved withsubcutaneous injection of fulvestrant in mice.[1] As such, not only may ZB716 be more convenient to administer in humans, it has far greaterbioavailability compared to fulvestrant and hence may allow for greater systemic exposure and therapeutic benefit.[1]
ZB716 produces fulvestrant as anactive metabolitein vivo in mice, with approximately 10 to 15% of the drug being converted into it.[1] As such, most of the effects are likely due to the parent drug.[1]
As of December 2020, it is in a phase I clinical trial for ER+/HER2- metastatic breast cancer.[2]
 | Thisantineoplastic orimmunomodulatorydrug article is astub. You can help Wikipedia byadding missing information. |
